Equity Overview
Price & Market Data
Price: $5.38
Daily Change: -$0.14 / 2.60%
Range: $5.27 - $5.62
Market Cap: $270,212,128
Volume: 241,939
Performance Metrics
1 Week: 0.37%
1 Month: -10.18%
3 Months: -31.81%
6 Months: -52.77%
1 Year: -25.48%
YTD: -34.55%
Company Details
Employees: 106
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer, as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is based in Boston, Massachusetts.